Pharmaceutical Market India: A Comprehensive Industry Analysis

NEW YORK, Sept. 24, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pharmaceutical Market India: A Comprehensive Industry Analysis

http://www.reportlinker.com/p01361263/Pharmaceutical-Market-India-A-Comprehensive-Industry-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical

Pharmaceutical Market India: A Comprehensive Industry Analysis provides you with a detailed investigation of the market size, segmentation, key players, SWOT analysis, influential Government policies, and business and economic environments. The report is supported by over 330 tables & figures.

The Indian pharmaceutical market (IPM) is presented as follows:

• By Company (e.g., CIPLA, SUN PHARMA, RANBAXY, PIRAMAL, ZYDUS CADILA, MANKIND, LUPIN)• By Segment (FORMULATIONs, APIs, BIOSIMILARs, CRAMS)• By Therapeutic Area (e.g., Cardiovascular, Diabetes, Cancer, Respiratory)• By Disease Category (Acute, Chronic)

A wealth of financial information is provided including:

• Up-to-date company financials, sales & revenue figures• India GDP, economic growth, export (bulk drug, formulations) figures• Indian health expenditure as a function of GDP• Growth change figures of emerging and developing countries (India, Russia, China, Brazil)• Economic growth figures of advanced economies (USA, UK, Germany, France, Italy, Spain, Japan, Canada)

SWOT, Economic and Business Environment specifics include:

• Key strengths, weaknesses and threats influencing leading player position within the IPM• Top five fastest growing Indian pharma market segments• Top five emerging opportunities within the IPM• Top pharmaceutical companies within the IPM by market share and revenue• Multinational penetration into the Indian Pharma Market• Comprehensive product portfolios, R&D activity and pipeline therapeutics • M&A activity and future strategies of top Indian pharmacos• Economic indicators, trade policy, merchandise and commercial trade statistics• Gross Domestic Product of India, historic and projection analysis• Indian economic outlook in comparison to advanced economies

This report highlights a number of significant Indian pharmacos and gives details of their operations, products, financials and business strategy.

• Aurobindo Pharma• Bharat Serums and Vaccines Ltd• Biocon Biopharmaceuticals• Cipla• Divis Laboratories• Dr Reddy's Laboratories• Lupin• Mankind Pharma• Panacea Biotech• Piramal Group• Ranbaxy Laboratories• Reliance Life Sciences• Serum Institute of India• Sun Pharmaceuticals• Zydus Cadila

Forecast projections and future growth rates are provided to give you a forthcoming perspective of this growing industry. Current developments relating to patent expirations, government funding, and regulations are discussed. The emerging trends that appear in key sub-markets such as generics, oncology, cardiovascular, diabetes and vaccines are elucidated and analysed.

What you will gain:

• An in-depth understanding of the Indian biopharmaceutical market and it's environment

• Current market facts, figures and product lines of key players in the industry

• An insight into how generic therapeutics will propagate the Indian biopharmaceutical market

• Knowledge of how the Indian biopharma market will integrate into the global healthcare market

• Information on key government policies

• Strategies on how to adapt and restructure current business models to this industry

This report will tell you if the companies mentioned are:

• Strong, competitive players

• Pooling their resources for specific growth and therapeutic areas

• Investing strategically in R&D

• Have a history of strategic M&A activity

The Pharmaceutical Market India report also provides you with a comprehensive company directory of key people and contact details.

Table of Contents

1.0 Summary 101.1 Objectives of Report 101.2 Scope of Study 111.3 Data Sources and Methodology 111.4 Key Findings and Observations 111.5 Executive Summary 12

2.0 Epidemiology and Disease Overview 16

2.1 Cardiovascular Disease 20

2.2 Infectious Disease 22

2.3 Respiratory Infections 22

2.4 Tuberculosis 24

2.5 HIV 29

2.6 Hepatitis 30

2.7 Typhoid Fever 31

2.8 Dengue Fever 31

2.9 Diabetes 31

2.10 Cancer 33

2.11 Chronic Respiratory Disease- Asthma and COPD 37

3.0 Twelfth Five Year Plan – A Boost for Scientific Research and Development 39

4.0 Economic and Business Environment 41

4.1 Economic Indicators, Trade Policy and Merchandise and Commercial Trade Statistics 41

4.2 Gross Domestic Product of India, Historic and Projection Analysis 43

4.3 Global and India Economic Outlook 2010-2013 44

4.4 Indian Economic Outlook in Comparison to Advanced Economies (US, Europe) 46

5.0 Indian Pharmaceutical Industry 495.1 Overview 495.2 Formulations Market 505.3 Active Pharmaceutical Ingredient Market 515.4 Biosimilar Market 525.5 Contract Research and Manufacturing Service (CRAMS) 525.6 Indian Pharmaceutical Industry Market 545.7 Evaluation of Market Share by Therapeutic Area 575.8 Key Players 58

6.0 Indian Pharmaceutical Company Profiles and Financial Data 60

6.1 Aurobindo Pharma 60

6.2 Bharat Serums and Vaccines Ltd 67

6.3 Biocon Biopharmaceuticals 69

6.4 Cipla 78

6.5 Divis Laboratories 82

6.6 Dr Reddy's Laboratories 84

6.7 Lupin 89

6.8 Mankind Pharma 100

6.9 Panacea Biotech 106

6.10 Piramal Group 114

6.11 Ranbaxy Laboratories 120

6.12 Reliance Life Sciences 126

6.13 Serum Institute of India 129

6.14 Sun Pharmaceuticals 132

6.15 Zydus Cadila 136

7.0 SWOT Analysis of Indian Pharmaceutical Market 1437.1 Growth Factors 1437.2 Strengths of Indian Pharmaceutical Industry 1447.3 Main Weaknesses 1447.4 Significant Opportunities within the Indian Pharmaceutical Industry 1457.5 Threats and Considerations 146

8.0 Company Directory and Key People 148

8.1 Aurobindo Pharma 148

8.2 Bharat Serums and Vaccines Ltd 149

8.3 Biocon Biopharmaceuticals 150

8.4 Cipla 152

8.5 Divis laboratories 152

8.6 Dr Reddy's Laboratories 154

8.7 Lupin 156

8.8 Panacea Biotech 157

8.9 Reliance Life Sciences 159

9.0 Appendix 1609.1 Comprehensive List of Pharmaceutical Company's in India 160

Exhibits List

Exhibit 2.1: Key Statistics: India 16

Exhibit 2.2: National Expenditure on Health (Indian Rupee) 2000 – 2011 16

Exhibit 2.3: Top Ten Causes of Mortality in India 2008-2030 18

Exhibit 2.4: Estimated Number of Deaths Due to Most Prevalent Disease States, India 18

Exhibit 2.5: Historic and Projected Death Rates Due to Cardiovascular and Cancer, India 2004-2030 19

Exhibit 2.6: Trend of Communicable and Non-Communicable Disease Burden in Developing World 1970-2030 19

Exhibit 2.7: Cardiovascular Mortality by Indian State 20

Exhibit 2.8: Factors Contributing to High Prevalence of Cardiovascular Disease in India 21

Exhibit 2.9: Distribution of Cause of Death in Children under Five, India 22

Exhibit 2.10: Global Incidence of Childhood Clinical Pneumonia 23

Exhibit 2.11: Global Distribution of Deaths from Pneumonia and other Causes in Children 23

Exhibit 2.12: Revised National Tuberculosis Control Program (RNTCP) Statistics 2005-Present 24

Exhibit 2.13: Estimated Global Tuberculosis Incidence Rates 2011 25

Exhibit 2.14: India TB Statistics by State, Population Covered, Diagnosis, Treatment Relapse

and HIV Co-infection 25

Exhibit 2.15: Estimated Global HIV Prevalence in New TB Cases 2011 26

Exhibit 2.16: Number of MDR-TB Cases Estimated to Occur Among Notified Pulmonary TB Cases 2011 27

Exhibit 2.17: Countries That Had Notified of at Least One XDR-TB Case by end of 2011 27

Exhibit 2.18: TB Vaccine Development Pipeline 2012 28

Exhibit 2.19: HIV Prevalence in India 2004-2009 29

Exhibit 2.20: Routes of HIV Transmission in India 2011 29

Exhibit 2.21: Global Hepatitis E Virus Endemicity 30

Exhibit 2.22: Prevalence of Diabetes by Indian Region 32

Exhibit 2.23: Global Prevalence of Undiagnosed Diabetes, 2011 32

Exhibit 2.24: Incidence and Mortality Rates for Top Sixteen Cancers in India – Both Sexes 33

Exhibit 2.25: Prevalence of Cancer Cases and Deaths in India, Male and Female 34

Exhibit 2.26: Incidence and Mortality Rates for Top Sixteen Cancers in India - Men 34

Exhibit 2.27: Incidence and Mortality Rates for Top Sixteen Cancers in India – Women 35

Exhibit 2.28: Percentage Incidence Distribution of the most Frequent Cancers in India, Both Sexes 36

Exhibit 2.28: Percentage Mortality Distribution of the most Frequent Cancers in India, Both Sexes 36

Exhibit 2.29: Five Year Prevalence and Incidence of Top Twenty Cancer's in India 36

Exhibit 2.30: Mortality Rate Attributable to Chronic Obstructive Pulmonary Disease Globally 37

Exhibit 3.1: India's Twelve Year Plan – Key Points in Relation to Science Research and Development 40

Exhibit 3.2: Budget for Specific Scientific Departments under India's Twelfth Five Year Plan 40

Exhibit 4.1: World Trade Organisation Basic Indicators on India 41

Exhibit 4.2: World Trade Organisation Trade Policy of India 42

Exhibit 4.3: World Trade Organisation Merchandise Trade Statistics: India 42

Exhibit 4.4: World Trade Organisation Commercial Services Trade Statistics: India 43

Exhibit 4.5: World Trade Organisation Industrial Property Statistics: India 43

Exhibit 4.6: India GDP Figures 2011-2018 43

Exhibit 4.7: India Health Expenditure as a Percentage of GDP 2000-2010 44

Exhibit 4.8: Global, Emerging Market and Developing Countries Economic Growth Change 2010-2013 44

Exhibit 4.9: Global, Emerging Market and Developing Countries and India Economic Growth Change 2010- 2013 44

Exhibit 4.10: Global, Emerging Market and Developing Countries and Russia Economic Growth Change 2010-2013 44

Exhibit 4.11: Global, Emerging Market and Developing Countries and China Economic Growth Change 2010-2013 45

Exhibit 4.12: Global, Emerging Market and Developing Countries and Brazil Economic Growth Change 2010-2013 46

Exhibit 4.13: Global, US and Germany Economic Growth 2010-2013 46

Exhibit 4.14: US and UK Gross Domestic Product per capita Forecast 2010-2017 47

Exhibit 4.15: Global, France and Italy Economic Growth 2010-2013 47

Exhibit 4.16: France, Germay and Italy Gross Domestic Product per capita Forecast 2010-2017 48

Exhibit 4.17: Global, UK and Spain Economic Growth 2010-2013 48

Exhibit 4.18: Global, Japan and Canada Economic Growth 2010-2013 48

Exhibit 4.19: India, Brazil and China Gross Domestic Product per capita Forecast 2010-2017 49

Exhibit 5.1: Four Major Areas of the Indian Pharmaceutical Industry 49

Exhibit 5.2: Indian Pharmaceutical Industry IPM and Exports 2003-2015 50

Exhibit 5.3: Indian Pharmaceutical Industry Bulk Drug Exports 2003-2015 50

Exhibit 5.4: Indian Pharmaceutical Industry Formulation Exports 2003-2015 51

Exhibit 5.5: Indian Pharmaceutical Industry Domestic Formulations 2003-2015 51

Exhibit 5.6: Geographic Distribution of India's Active Pharmaceutical Ingredient Exports, 2012 52

Exhibit 5.7: Current Trends of the Global Biosimilar Market 52

Exhibit 5.8: Main Therapeutic Areas of the Future Biosimilar Market 53

Exhibit 5.9: Market Share ($ Billions) of Contract Manufacturing and Research within Indian CRAMS Industry 53

Exhibit 5.10: Market Share (Percentage) of Contract Manufacturing and Research within Indian CRAMS Industry 54

Exhibit 5.11: Indian Contract Research and Manufacturing Services (CRAMS) Market 2010-2015 54

Exhibit 5.12: Leading Players of the Indian Pharmaceutical Market 54

Exhibit 5.13: India - Significant Economic Indicators 55

Exhibit 5.14: Positive Factors Influencing the Indian Pharmaceutical Market 55

Exhibit 5.15: Quantitative Market Share of Acute and Chronic Therapy in India, 2012 56

Exhibit 5.16: Multinational Company Penetration into Indian Pharmaceutical Market 2011 56

Exhibit 5.17: Key Factors Influencing Leading Player Position in India Pharma Market 57

Exhibit 5.18: Indian Pharmaceutical Market Share (%) by Therapeutic Area 57

Exhibit 5.19: Top Five Fastest Growing Indian Pharma Market Segments, 2012 57

Exhibit 5.20: Top Five Emerging Opportunities within the Indian Pharmaceutical Market 57

Exhibit 5.21: Top Pharmaceutical Companies within the Indian Pharmaceutical Market by Market Share and Revenue 58

Exhibit 5.22: Percentage Market Share of Leading Players in the Indian Pharmaceutical Market 58

Exhibit 5.23: Revenue Reported from Leading Players of Indian Pharmaceutical Market 2012 59

Exhibit 6.1: Aurobindo Pharma Therapeutic Areas of Interest 60

Exhibit 6.2: Aurobindo Pharma Formulation Unit Accreditation 60

Exhibit 6.3: Aurobindo Pharma Range of Anti-Infective Formulations 60

Exhibit 6.4: Aurobindo Pharma Therapeutic Areas of Interest 61

Exhibit 6.5: Aurobindo Pharma Antiretroviral Therapeutic Product Portfolio 61

Exhibit 6.6: Aurobindo Pharma Antiosteoporotic Therapeutic Product Portfolio 61

Exhibit 6.7: Aurobindo Pharma Antihypertensive Therapeutic Product Portfolio 62

Exhibit 6.8: Aurobindo Pharma Antiasthmatic Therapeutic Product Portfolio 62

Exhibit 6.9: Aurobindo Pharma Beta-Lactam-Antibiotic Product Portfolio 62

Exhibit 6.10: Aurobindo Pharma Anti Erectile Dysfunction Product Portfolio 62

Exhibit 6.11: Aurobindo Pharma Antiosteoporotic Product Portfolio 62

Exhibit 6.12: Aurobindo Pharma Alzheimer's Product Portfolio 62

Exhibit 6.13: Aurobindo Pharma Antibiotic Product Portfolio 62

Exhibit 6.14: Aurobindo Pharma Antidepressant Product Portfolio 63

Exhibit 6.15: Aurobindo Pharma Antidiabetic Product Portfolio 63

Exhibit 6.16: Aurobindo Pharma Antiemetic Product Portfolio 63

Exhibit 6.17: Aurobindo Pharma Antiepileptic Therapeutic Portfolio 63

Exhibit 6.18: Aurobindo Pharma Cardiovascular Therapeutic Portfolio 64

Exhibit 6.19: Aurobindo Pharma CNS Therapeutic Portfolio 64

Exhibit 6.20: Aurobindo Pharma Pain Management Therapeutic Portfolio 65

Exhibit 6.21: Aurobindo Pharma Consolidated Revenue 2009-2012 65

Exhibit 6.22: Aurobindo Pharma Subsidiary Companies 66

Exhibit 6.23: Aurobindo Pharma Long Term Growth Strategies 67

Exhibit 6.24: Bharat Serums and Vaccines Significant Milestones 68

Exhibit 6.25: Bharat Serums and Vaccines Range of Products 68

Exhibit 6.26: Bharat Serums and Vaccines Plasma Serum Product Portfolio 68

Exhibit 6.27: Bharat Serums and Vaccines Monoclonal Antibody Product Portfolio 68

Exhibit 6.28: Bharat Serums and Vaccines Equine Antitoxin and Serum Product Portfolio 68

Exhibit 6.29: Bharat Serums and Vaccines Cardiovascular Product Portfolio 69

Exhibit 6.30: Bharat Serums and Vaccines Anti-microbial Product Portfolio 69

Exhibit 6.31: Bharat Serums and Vaccines Anti-fungal Product Portfolio 69

Exhibit 6.32: Bharat Serums and Vaccines Anaesthesia Product Portfolio 69

Exhibit 6.33: Bharat Serums and Vaccines Hormone Product Portfolio 69

Exhibit 6.34: Biocon Biopharmaceuticals Business Outline 70

Exhibit 6.35: Biocon Biopharmaceuticals Five Key Business Areas 70

Exhibit 6.36: Biocon Biopharmaceuticals Subsidiary Companies 70

Exhibit 6.37: Biocon Biopharmaceuticals Important Milestones 71

Exhibit 6.38: Biocon Biopharmaceuticals Active Pharmaceutical Ingredients (APIs) Product Areas 72

Exhibit 6.39: Biocon Biopharmaceuticals Active Biological Product Areas 72

Exhibit 6.40: Biocon Biopharmaceuticals Diabetes Branded Formulations 73

Exhibit 6.41: Biocon Biopharmaceuticals Oncology Branded Therapeutics 73

Exhibit 6.42: Biocon Biopharmaceuticals Nephrology Branded Therapeutics 73

Exhibit 6.43: Biocon Biopharmaceuticals Cardiology Branded Therapeutics 74

Exhibit 6.44: Biocon Biopharmaceuticals Comprehensive Care Branded Therapeutics 74

Exhibit 6.45: Biocon Biopharmaceuticals Immunotherapy Branded Therapeutics 74

Exhibit 6.46: Biocon Biopharmaceuticals BioTherapy Branded Therapeutics 75

Exhibit 6.47: Biocon Biopharmaceuticals – Syngene Service Platform 76

Exhibit 6.48: Biocon Biopharmaceuticals – Clinigene Service Platform 76

Exhibit 6.49: Biocon Biopharmaceuticals Revenue 2008-2012 77

Exhibit 6.50: Biocon Biopharmaceuticals Revenue 2008-2012 77

Exhibit 6.51: Biocon Biopharmaceuticals Profits from Operations 2008-2012 77

Exhibit 6.52: Biocon Biopharmaceuticals Profits from Operations 2008-2012 78

Exhibit 6.53: Cipla Important Milestones 78

Exhibit 6.54: Cipla Main Therapeutics Areas of Interest 79

Exhibit 6.55: Cipla Export Market Share FY2011-2012 79

Exhibit 6.56: Cipla Sales and Other Income Exhibits 2003-2012 80

Exhibit 6.57: Cipla Profit after Tax Exhibits 2003-2012 80

Exhibit 6.58: Cipla Significant Product Launches During FY 2011-2012 81

Exhibit 6.59: Cipla Significant Active Pharmaceutical Ingredient Commercialisation Launches During FY 2011-2012 81

Exhibit 6.60: Divis Laboratories Important Milestones 82

Exhibit 6.61: Divis Laboratories Product Category Portfolio 82

Exhibit 6.62: Divis Laboratories Product List 83

Exhibit 6.63: Divis Laboratories Income From Operations 2006-2012 84

Exhibit 6.64: Divis Laboratories Future Pipeline Portfolio 84

Exhibit 6.65: Dr Reddy's Therapeutic Areas of Interest 85

Exhibit 6.66: Dr Reddy's Laboratories – Important Milestones 85

Exhibit 6.67: Dr Reddy's Labs Top Active Pharmaceutical Ingredients 86

Exhibit 6.68: Dr Reddy's Labs Top Brands in India 86

Exhibit 6.69: Dr Reddy's Laboratories Annual Revenue Exhibits 2003-2012 87

Exhibit 6.70: Dr Reddy's Laboratories Historical Revenue Exhibits 2003-2012 (Global) 87

Exhibit 6.71: Dr Reddy's Laboratories Geographical Revenue Percentage 2012 87

Exhibit 6.72: Dr Reddy's Key Brand Revenue in Russia 2011-2012 88

Exhibit 6.73: Dr Reddy's Key Brand Revenue in India 2011-2012 88

Exhibit 6.74: Dr Reddy's Therapeutic Agents and Classes undergoing Clinical Trials 89

Exhibit 6.75: Lupin Significant Milestones 89

Exhibit 6.76: Lupin Ltd Formulations Product Portfolio 90

Exhibit 6.77: Lupin Ltd Active Pharmaceutical Ingredient Product Portfolio 92

Exhibit 6.78: Lupin Ltd Formulation and Active Pharmaceutical Ingredient Business Contribution 93

Exhibit 6.79: Lupin Ltd Formulations and Active Pharmaceutical Ingredient Exports 2006-2012 93

Exhibit 6.80: Lupin Ltd Formulation and Active Pharmaceutical Ingredient Revenue Contribution 2012 94

Exhibit 6.81: Lupin Ltd Geographic Breakdown of Revenue 2012 94

Exhibit 6.82: Lupin Ltd Net Global Sales 2008-2012 94

Exhibit 6.83a: Lupin Ltd Profit Before Tax 2008-2012 95

Exhibit 6.83b: Lupin Ltd Formulation Sales 2006-2012 Indian Market 95

Exhibit 6.84: Lupin Ltd Top Product Brands in the Indian Market and Ranking 96

Exhibit 6.85: Lupin Ltd Therapeutic Area Growth Increase in Comparison to Overall Market Growth 96

Exhibit 6.86: Lupin Pharma Key Products and Rank in the Indian Market 96

Exhibit 6.87: Lupin Respira Key Products and Rank in the Indian Market 96

Exhibit 6.88: Lupin Endeavour Key Products and Rank in the Indian Market 97

Exhibit 6.89: Lupin Maxter Key Products and Rank in the Indian Market 97

Exhibit 6.90: Lupin Pinnacle CVS Key Products and Rank in the Indian Market 97

Exhibit 6.90: Lupin Diabetes Care Key Products and Rank in the Indian Market 97

Exhibit 6.91: Lupin Mindvision Key Products and Rank in the Indian Market 97

Exhibit 6.92: Lupin Ikonic Key Products and Rank in the Indian Market 97

Exhibit 6.93: Lupin Pharmaceuticals Formulation Sales US Market 2007-2012 98

Exhibit 6.94: Lupin Ltd Performance in Top Five Generic Pharmaceutical Companies in the US Market 98

Exhibit 6.95: Lupin Ltd Percentage Market Share within US Generics Market 99

Exhibit 6.96: Lupin Ltd (Kyowa Pharmaceutical) Sales in Japanese Market 2008-2012 99

Exhibit 6.97: Lupin Ltd Division of Sales by Therapeutic Area 100

Exhibit 6.98: Lupin Ltd Advanced Drug Delivery System Platform Portfolio 100

Exhibit 6.99: Lupin Ltd Research and Development Areas of Expertise 100

Exhibit 6.100: Mankind Pharma Company Divisions 101

Exhibit 6.101: Mankind Pharma Key Milestones 101

Exhibit 6.102: Mankind Pharma Therapeutic Areas of Interest 102

Exhibit 6.103: Mankind Pharma Prescription Product Areas 102

Exhibit 6.104: Mankind Pharma Top Ten Brands 102

Exhibit 6.105: Mankind Pharma Diabetic Product Brands 102

Exhibit 6.106: Mankind Pharma Hyperthyroidism Product Brands 103

Exhibit 6.107: Mankind Pharma Cough Product Brands 103

Exhibit 6.108: Mankind Pharma Malaria Product Brands 103

Exhibit 6.109: Mankind Pharma Migraine Product Brands 103

Exhibit 6.110: Mankind Pharma Anti-viral Product Brands 103

Exhibit 6.111: Mankind Pharma Steroid Product Brands 103

Exhibit 6.112: Mankind Pharma Dermatology Product Brands 104

Exhibit 6.113: Mankind Pharma Ophthalmology Product Brands 104

Exhibit 6.114: Mankind Pharma Gynaecology Product Brands 104

Exhibit 6.115: Mankind Pharma Antibiotic Product Brands 105

Exhibit 6.116: Mankind Pharma Asthmatic Product Brands 105

Exhibit 6.117: Panacea Biotech Strategic Business Unit Structure 107

Exhibit 6.118: Panacea Biotech Therapeutic Areas of Interest 107

Exhibit 6.119: Panacea Biotech Leading Brands in India 107

Exhibit 6.120: Panacea Biotech Pain Management Therapy Portfolio 108

Exhibit 6.121: Panacea Biotech Diacar Alpha and Diacar Delta SBU Oral Hypoglycemic Product Range 108

Exhibit 6.122: Panacea Biotech Diacar Alpha and Diacar Delta SBU Cardiovascular Product Range 108

Exhibit 6.123: Panacea Biotech Vaccine Portfolio 109

Exhibit 6.124: Panacea Biotech Diabetes Management Portfolio 109

Exhibit 6.125: Panacea Biotech Anti-Osteoporotic Portfolio 109

Exhibit 6.126: Panacea Biotech Antipyretic, Anti-inflammatory and Analgesic Portfolio 109

Exhibit 6.127: Panacea Biotech Renal Disease Management Portfolio 109

Exhibit 6.128: Panacea Biotech Gastro Intestinal Product Portfolio 110

Exhibit 6.129: Panacea Biotech Constipation Product Portfolio 110

Exhibit 6.130: Panacea Biotech Tuberculosis Product Portfolio 110

Exhibit 6.131: Panacea Biotech Cough/Cold Product Portfolio 110

Exhibit 6.132: Panacea Biotech Brand Standing and Market Share (India) - Diabetes and Cardiac Care 110

Exhibit 6.133: Panacea Biotech Brand Standing and Market Share (India) - Pain Management 110

Exhibit 6.134: Panacea Biotech Brand Standing and Market Share (India) – Tuberculosis Treatment 110

Exhibit 6.135: Panacea Biotech Brand Standing and Market Share (India) – Gastrointestinal Treatment 111

Exhibit 6.136: Panacea Biotech Brand Standing and Market Share (India) – Anti-Haemorrhoidal 111

Exhibit 6.137: Panacea Biotech Brand Standing and Market Share (India) – Penicillins 111

Exhibit 6.138: Panacea Biotech Current Patents for Licencing 111

Exhibit 6.139: Panacea Biotech Net Turnover 2002-2012 113

Exhibit 6.140: Panacea Biotech Net Turnover 2002-2012 113

Exhibit 6.141: Panacea Biotech Geographic Distribution of Sales, 2010-2012 114

Exhibit 6.142: Panacea Biotech Geographic Distribution of Sales, 2010-2012 114

Exhibit 6.143: Key Milestones in Piramal Group History 115

Exhibit 6.144: Piramal Distribution of Sales (Percentage) 2012 117

Exhibit 6.145: Piramal Distribution of Pharma Solutions Domestic and International Sales 2012 117

Exhibit 6.146: Piramal Pharma Solutions Sales from Domestic and International Assets 2011-2012 117

Exhibit 6.147: Piramal Oncology Therapeutic Pipeline 119

Exhibit 6.148: Piramal Inflammation Therapeutic Pipeline 119

Exhibit 6.149: Piramal Diabetic and Metabolic Disease Therapeutic Pipeline 119

Exhibit 6.150: Piramal Infectious Disease Therapeutic Pipeline 119

Exhibit 6.151: Ranbaxy Laboratories – Therapeutic Markets of Interest 120

Exhibit 6.152: Ranbaxy's Oral Platform Technologies using a Novel Drug Delivery System 120

Exhibit 6.153: Ranbaxy Laboratories - Top Ten Therapeutics 120

Exhibit 6.154: Ranbaxy Key Merger and Acquisition Activity since 2006 121

Exhibit 6.155: List of Ranbaxy Subsidiary Companies 121

Exhibit 6.156: Ranbaxy – Future Therapeutic Areas 122

Exhibit 6.157: Ranbaxy Global Sales by Geographical Region 123

Exhibit 6.158: Ranbaxy Global Sale Figures by Geographical Region 123

Exhibit 6.159: Ranbaxy Geographical Market Share Percentage 123

Exhibit 6.160: Ranbaxy Developed and Emerging Market Share 124

Exhibit 6.161: Ranbaxy Sales Figures, USA and Canada 124

Exhibit 6.162: Ranbaxy Sales Figures, Europe 125

Exhibit 6.163: Ranbaxy Top Sellers in India 125

Exhibit 6.164: Ranbaxy Sales Figures, India 126

Exhibit 6.165: Ranbaxy Market Share of Top Therapeutics, India 126

Exhibit 6.166: Ranbaxy Launches by Geographical Region 126

Exhibit 6.167: Reliance Life Sciences Biopharmaceutical Product Areas 127

Exhibit 6.168: Reliance Life Sciences Pharmaceutical Product Areas 127

Exhibit 6.169: Reliance Life Sciences Clinical Research Services 128

Exhibit 6.170: Reliance Life Sciences Regenerative Medicine Product Areas 128

Exhibit 6.171: Reliance Life Sciences Molecular Medicine Product Areas 128

Exhibit 6.172: Reliance Life Science Plasma Protein Product Portfolio 128

Exhibit 6.173: Reliance Life Science Biosimilar Product Portfolio 128

Exhibit 6.174: Reliance Life Science Pharmaceutical Product Portfolio 128

Exhibit 6.175: Reliance Life Science Regenerative Medicine Product Portfolio 128

Exhibit 6.176: Reliance Life Science R&D Activities 129

Exhibit 6.177: Serum Institute of India Significant Milestones 130

Exhibit 6.178a: Serum Institute of India Manufactured Products 130

Exhibit 6.178b: Serum Institute of India Marketed Products 131

Exhibit 6.179: Serum Institute of India Exported Products 131

Exhibit 6.180: Serum Institute of India Product Pipeline 132

Exhibit 6.181: Sun Pharmaceuticals – Important Milestones 133

Exhibit 6.182: Sun Pharmaceuticals Revenue Stream 2011-2012 (percentage) 134

Exhibit 6.183: Sun Pharmaceutical Revenue Stream 2011-2012 ($ Millions) 134

Exhibit 6.184: Sun Pharmaceuticals Percentage Breakdown of Therapeutic Area Sales 2012 135

Exhibit 6.185: Sun Pharmaceuticals Top Ten Branded Generics in India 135

Exhibit 6.186: Sun Pharmaceuticals Number of Drug Approvals by Therapeutic Area 136

Exhibit 6.187: Zydus Research Centre Speciality Areas of Research 137

Exhibit 6.188: Zydus Cadila Vaccine R&D Areas of Research 137

Exhibit 6.189: Zydus Cadila Global 'Beyond the Billion' Business Development Strategy 138

Exhibit 6.190: Zydus Cadila Top Formulation Brands in the Indian Market 138

Exhibit 6.191: Zydus Cadila New Molecular Entities in Development Pipeline 139

Exhibit 6.192: Zydus Cadila Biosimilar Therapeutics in Development Pipeline 139

Exhibit 6.193: Zydus Cadila Indian Formulation Market Distribution (%) by Therapeutic Area 2012 140

Exhibit 6.194: Zydus Cadila Gross Sales 2006-2012 141

Exhibit 6.195: Zydus Cadila List of Subsidiary Companies 141

Exhibit 6.196: Zydus Cadila Key Acquisitions 1995-2012 142

Exhibit 6.197: Zydus Cadila Research and Development Areas of Interest 142

Exhibit 7.1: Main Growth Factors of the Indian Pharmaceutical Market 143

Exhibit 7.2: Indian Health Insurance Coverage Statistics 2010-2020 143

Exhibit 7.3: Strengths of the Indian Pharmaceutical Market 144

Exhibit 7.4: Weaknesses of the Indian Pharmaceutical Market 144

Exhibit 7.5: Opportunities within the Indian Pharmaceutical Market 145

Exhibit 7.6: Threats to the Indian Pharmaceutical Market 147

Exhibit 8.1: Aurobindo Pharma Key Contact Details 148

Exhibit 8.2: Aurobindo Pharma Board of Directors and Key Personnel 148

Exhibit 8.3: Bharat Serums and Vaccines Ltd General Contact Details 149

Exhibit 8.4: Bharat Serums and Vaccines Ltd Board of Directors 149

Exhibit 8.5: Biocon Biopharmaceuticals Key Contact Details 150

Exhibit 8.6: Biocon Biopharmaceuticals Board of Directors 151

Exhibit 8.7: Biocon Biopharmaceuticals Key Management Team 151

Exhibit 8.8: Cipla Executive Directors 152

Exhibit 8.9: Cipla Non-Executive/Independent Directors 152

Exhibit 8.10: Cipla Corporate Contact Details 152

Exhibit 8.11: Divis Laboratories Key Contact Details 152

Exhibit 8.12: Divis Laboratories Key People 154

Exhibit 8.13: Dr Reddy's Laboratories Contact Information 154

Exhibit 8.14: Dr Reddy's Laboratories Key People 155

Exhibit 8.15: Dr Reddy's Laboratories Board of Directors 155

Exhibit 8.16: Dr Reddy's Audit Committee Members 156

Exhibit 8.17: Dr Reddy's Nomination, Governance & Compensation Committee Members 156

Exhibit 8.18: Dr Reddy's Risk Management Committee Members 156

Exhibit 8.19: Dr Reddy's Science, Technology and Operations Committee Members 156

Exhibit 8.20: Dr Reddy's Shareholders' Grievance Committee Members 156

Exhibit 8.21: Dr Reddy's Investment Committee Members 156

Exhibit 8.22: Dr Reddy's Management Committee Members 156

Exhibit 8.23: Lupin Board of Directors 156

Exhibit 8.24: Lupin Key Management Players 157

Exhibit 8.25: Lupin Ltd General Contact Details 157

Exhibit 8.26: Panacea Biotech – Whole Time Directors 157

Exhibit 8.27: Panacea Biotech – Independent Directors 157

Exhibit 8.28: Panacea Biotech – Investor Contact Details 158

Exhibit 8.29: Panacea Biotech – General Contact Details 158

Exhibit 8.30: Reliance Life Sciences – General Contact Details 159

Companies Mentioned

• Aurobindo Pharma

• Bharat Serums and Vaccines Ltd

• Biocon Biopharmaceuticals

• Cipla

• Divis Laboratories

• Dr Reddy's Laboratories

• Lupin

• Mankind Pharma

• Panacea Biotech

• Piramal Group

• Ranbaxy Laboratories

• Reliance Life Sciences

• Serum Institute of India

• Sun Pharmaceuticals

• Zydus Cadila

To order this report: Pharmaceutical Market India: A Comprehensive Industry Analysishttp://www.reportlinker.com/p01361263/Pharmaceutical-Market-India-A-Comprehensive-Industry-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical

Contact Clare: clare@reportlinker.com
US:(339) 368 6001
Intl:+1 339 368 6001

 

Search